Conversation with The Cancer LetterRegulatory News Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director November 14, 2025Vol.51 No.42By Paul Goldberg
Guest Editorial Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA November 14, 2025Vol.51 No.42By Ellen V. Sigal
Regulatory News FDA to remove black box warnings on hormone therapy for menopauseTrump-era “gold standard science” is not to be confused with gold standard of scientific evidence November 14, 2025Vol.51 No.42By Claire Marie Porter
Trials & Tribulations Smoldering multiple myeloma: Rethinking the waiting game November 14, 2025Vol.51 No.42By C. Ola Landgren
Sponsored Advancing symptom science at City of Hope and across the globe November 14, 2025Vol.51 No.42By Jeannine M. Brant
FreeIn the Archives How a neuroendocrine cancer survivor fueled 20 years of researchNETRF celebrates 20 years, $40 million in research funding November 14, 2025Vol.51 No.42
PodcastThe Directors The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery“This has always made our environment stronger, not weaker.” November 07, 2025Vol.51 No.41By Jacquelyn Cobb and Paul Goldberg
Regulatory News CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”Cancer advocates express concern about comments that signal trouble for accelerated approval November 07, 2025Vol.51 No.41By Claire Marie Porter and Paul Goldberg
Guest Editorial How George Tidmarsh crossed the FDA-industry Rubicon November 07, 2025Vol.51 No.41By Mikkael A. Sekeres
Guest Editorial How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care November 07, 2025Vol.51 No.41By Kathy Davy
